BioSpace News Archive

Seven Bridges, the industry-leading bioinformatics ecosystem provider, today announced the formation of its strategic advisory board tasked with advising Seven Bridges leadership team in its mission to accelerate scientific discovery and speed the path from raw experimental data to new treatments and diagnostic

eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the targeted inhibition of coagulation Factor XIa, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for EP-7041,

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Medicines Agency (EMA) has validated the company’s Type II variation marketing authorization application for AYVAKYT® (avapritinib) for the treatment of advanced systemic mastocytosis (SM).

Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma and other cancers, announced that its prior and upcoming GBM immunotherapy clinical studies and preclinical studies will be presented as e-posters at the upcoming American Association for Cancer Research Virtual Annual Meeting 2021, April 10-15 and May 17-21.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on HT-002 for the prevention and/or treatment of Sars-CoV-2, or COVID-19.

The Defense Advanced Research Projects Agency (DARPA) has awarded the Georgia Tech Research Institute (GTRI) a seed other transaction agreement as part of their SenSARS program to develop a sensing platform to detect airborne SARS-CoV-2 particles.

Xentria Inc., a biopharmaceutical company focused on developing novel biologics and biosimilars to address unmet clinical needs, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on February 26, 2021.

Janux Therapeutics today announced the close of a $56 million Series A financing led by Avalon Ventures and joined by new investors, OrbiMed and RA Capital Management, as well as existing investors, Bregua and Correlation Ventures

Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, announced today the successful completion of an oversubscribed $115 million Series C financing. Proceeds from the financing will be used to further develop the Company’s proprietary, next-generation CRISPR technology platform and to advance the Company’s pipeline of wholly-owned allogeneic immune cell therapies for oncology with best-in-class potential.

AUSTIN, TX / ACCESSWIRE / March 3, 2021 / Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced that it will participate in the H.C. Wainwright Global Life Sciences Conference taking place virtually March 9-10, 2021. Management will provide a pre-recorded presentation which will be available to registered investors on demand via the conference website. As part of the confere